These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32999263)

  • 1. The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions.
    Kambayashi H; Omori T; Saito S; Murasugi S; Kashiwagi H; Ito A; Yonezawa M; Nakamura S; Tokushige K
    Intern Med; 2020; 59(19):2343-2351. PubMed ID: 32999263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
    Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
    BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.
    Zhan S; Liu C; Li N; Li T; Tian Z; Zhao M; Wu D; Chen M; Zeng Z; Zhuang X
    Therap Adv Gastroenterol; 2022; 15():17562848221116666. PubMed ID: 36082178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
    Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
    Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy.
    Han SJ; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    Yonsei Med J; 2023 Feb; 64(2):111-116. PubMed ID: 36719018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of intestinal Behçet's disease.
    Hisamatsu T; Naganuma M; Matsuoka K; Kanai T
    Clin J Gastroenterol; 2014 Jun; 7(3):205-12. PubMed ID: 24883128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.
    Zhang Q; Ma C; Dong R; Xiang W; Li M; Ma Z; Yang Q
    Yonsei Med J; 2022 Feb; 63(2):148-157. PubMed ID: 35083900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.
    Li R; Li X; Zhou H; Shi Y; Wang F; Wu T; Liang J
    Front Immunol; 2023; 14():1205046. PubMed ID: 37287984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.
    Miyazaki H; Watanabe D; Okamoto N; Tokunaga E; Ku Y; Takenaka H; Hoshi N; Ooi M; Kodama Y
    BMC Gastroenterol; 2022 Mar; 22(1):149. PubMed ID: 35346067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of tuberculosis is increased in Behçet’s disease compared to other rheumatological disorders after anti-TNFα treatments: a case series and review of the literature.
    Gazel Ü; Kocakaya D; Hicret Topçu İ; Ömer Karataş H; Karabacak M; Atagündüz MP; İnanç GN; Alibaz Öner F; Direskeneli RH
    Turk J Med Sci; 2021 Aug; 51(4):1689-1694. PubMed ID: 33535732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical outcomes of intestinal Behçet's disease: A 30-year cohort study at a tertiary hospital in South Korea.
    Park J; Park SJ; Park JJ; Kim TI; Cheon JH
    J Gastroenterol Hepatol; 2023 Mar; 38(3):386-392. PubMed ID: 36346041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease.
    Imamura Y; Kurokawa MS; Yoshikawa H; Nara K; Takada E; Masuda C; Tsukikawa S; Ozaki S; Matsuda T; Suzuki N
    Clin Exp Immunol; 2005 Feb; 139(2):371-8. PubMed ID: 15654837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Saccharomyces cerevisiae antibody in intestinal Behçet's disease patients: relation to clinical course.
    Choi CH; Kim TI; Kim BC; Shin SJ; Lee SK; Kim WH; Kim HS
    Dis Colon Rectum; 2006 Dec; 49(12):1849-59. PubMed ID: 17080284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
    Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
    J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept in the treatment of intestinal Behcet's disease.
    Ma D; Zhang CJ; Wang RP; Wang L; Yang H
    Cell Biochem Biophys; 2014 Jul; 69(3):735-9. PubMed ID: 24622940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?
    Kim DH; Cheon JH
    Yonsei Med J; 2016 Jan; 57(1):22-32. PubMed ID: 26632379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
    Lee JH; Kim TN; Choi ST; Jang BI; Shin KC; Lee SB; Shim YR
    Korean J Intern Med; 2007 Mar; 22(1):24-7. PubMed ID: 17427642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
    Miyagawa I; Nakano K; Iwata S; Nakayamada S; Saito K; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Tanaka Y
    Arthritis Res Ther; 2019 Jun; 21(1):151. PubMed ID: 31228955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary artery aneurysms in Behçet's disease treated with anti-TNFα: A case series and review of the literature.
    Chan E; Sangle SR; Coghlan JG; D'Cruz DD
    Autoimmun Rev; 2016 Apr; 15(4):375-8. PubMed ID: 26777307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.